Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Share information
Events & Presentations
Financial reports
Financial calendar
Shareholder meetings
Shareholder information
Analyst coverage
Corporate governance
ESG
Newsroom
Press Releases
Image library
Glossary
Careers
Search
Research and development
Scientific papers and presentations
Sharing our discoveries and developments in our tireless pursuit of breakthrough therapies
Newest first
Oldest first
Posters & Papers
Presentations
Search
Reset
03/04/2019
COMBINATION OF DNA PLASMID VACCINE VB10.NEO AND BEMPEGALDESLEUKIN (NKTR-214) INDUCES STRONG NEOANTIGEN-SPECIFIC T CELL RESPONSES AND SUSTAINED TUMOR REGRESSION IN PRECLINICAL MODELS | Atlanta, April 2019
03/04/2019
HOW THE DNA VACCINE FORMAT USED IN A NOVEL MANNER CAN GENERATE POTENT CD8-DOMINATED NEOANTIGEN-SPECIFIC T CELL RESPONSES | San Francisco, March 2019
03/04/2019
GENERATING POTENT CD8-DOMINATED NEOANTIGEN-SPECIFIC T CELL RESPONSES WITH NOVEL DNA VACCINE | San Francisco, March 2019
03/04/2019
MANUFACTURING, REGULATORY AND LOGISTICS CHALLENGES IN THE RAPIDLY EVOLVING AREA OF THE INDIVIDUALISED THERAPEUTIC CANCER VACCINES | Boston, November 2018
03/04/2019
DEVELOPMENT OF A COST-EFFECTIVE PERSONALIZED CANCER NEOANTIGEN VACCINES INDUCING A UNIQUE CD8-DOMINATED T CELL RESPONSE | Basel, October 2018
Pages:
1
2
3
4
5
6
7
8
9
10
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
